Jacobs Levy Equity Management’s Antares Pharma, Inc. ATRS Stock Holding History

Jacobs Levy Equity Management’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-49,100	Closed	-$116K	–	1187
2020 Q1	$116K	Sell	49,100 -155,600	-76%	-$529K	﹤0.01%	951
2019 Q4	$962K	Buy	+204,700	New	+$838K	0.01%	698
2019 Q2	–	Sell	-110,408	Closed	-$335K	–	1061
2019 Q1	$335K	Sell	110,408 -200,992	-65%	-$651K	﹤0.01%	828
2018 Q4	$847K	Buy	+311,400	New	+$1.03M	0.01%	635
2017 Q3	–	Sell	-28,970	Closed	-$93K	–	1034
2017 Q2	$93K	Sell	28,970 -109,542	-79%	-$310K	﹤0.01%	897
2017 Q1	$393K	Buy	+138,512	New	+$333K	0.01%	687
2016 Q2	–	Sell	-75,300	Closed	-$66K	–	1257
2016 Q1	$66K	Buy	+75,300	New	+$72.9K	﹤0.01%	1056

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

CWM

Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Jacobs Levy Equity Management's ATRS Position: Q2 2020 in Review

Jacobs Levy Equity Management sold out of Antares Pharma, Inc. (ATRS) in Q2 2020, closing a stake of 49,100 shares — an estimated $116K sold.

Jacobs Levy Equity Management first reported a position in ATRS in Q1 2016 and held it in 7 quarters. The position peaked at $962K in Q4 2019. 159 funds tracked by Wall St. Rank hold ATRS as of Q2 2020.

Jacobs Levy Equity Management reported no remaining Antares Pharma, Inc. position as of Q2 2020 after selling out during the quarter.
Jacobs Levy Equity Management sold 49,100 Antares Pharma, Inc. shares in Q2 2020, an estimated $116K.
Jacobs Levy Equity Management first reported a position in Antares Pharma, Inc. in Q1 2016 and held it in 7 quarters.
Jacobs Levy Equity Management's Antares Pharma, Inc. position peaked at $962K in Q4 2019.
159 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2020, filed 17 Aug 2020.